Who can use Cablivi(Caplacizumab)?

CABLIVI is indicated for use in adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) as part of a combination treatment regimen.

Approved Indication and Patient Population

CABLIVI (caplacizumab-yhdp) is approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP). It must be used concomitantly with plasma exchange and immunosuppressive therapy, forming a critical component of the combined therapeutic approach for this thrombotic microangiopathy.

Related Columns

Caplacizumab(Cablivi)

CABLIVI (caplacizumab-yhdp) is specifically indicated for the treatment of...

WeChat Scan
Free Inquiry

Caplacizumab (Cablivi):Clinical Uses, Recommended Dosage, Treatment Effect

Caplacizumab (Cablivi) is a targeted therapeutic agent classified as a monoclonal antibody fragment (nanobody), primarily indicated for the treatment of adult acquired thrombotic thrombocytopenic purp...

Instructions for Caplacizumab

Caplacizumab is a nano-antibody drug, mainly used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It blocks the interaction between von Willebrand factor (vWF) and platelets, r...

Indications of Caplacizumab

Caplacizumab was approved by the U.S. Food and Drug Administration (FDA) in 2019 for marketing under the trade name CABLIVI for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP...